INC.

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote on AI in Healthcare at McKenna Institute Digital Innovation Summit

by

IRVINE, Calif., June 12, 2023 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans Keirstead will deliver a keynote at the Digital Innovation Summit, taking place June 12-13 in St. Andrews, New Brunswick, Canada. Hosted by the University of New Brunswick’s McKenna … Read more

Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)–The World’s First Oral Epothilone Anti-Cancer Drug

by

SAN FRANCISCO, June 12, 2023 /PRNewswire/ — Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce that the first patient has been enrolled today for a Phase 1 clinical … Read more

Creative Medical Technology Announces $2 Million Share Repurchase Program

by

PHOENIX, June 12, 2023 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up … Read more

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

by

SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by year end 2023 based on positive pivotal Phase 3 SIERRA results NEW YORK, June 12, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive … Read more

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

by

Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancers Observed partial response by RECIST 1.1 (~40% tumor reduction) at first post-baseline scan in a pre-treated patient having a high priority MTAP-deletion solid tumor type Clinical strategy focused on IDE397 combinations, including with AMG … Read more

Illumina announces CEO transition plan

by

SAN DIEGO, June 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, … Read more

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

by

CAMBRIDGE, Mass., June 9, 2023 /PRNewswire/ — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today presented updated preliminary data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy. Initial preliminary … Read more

ParagonX Holdings Reaches Agreement on Major Acquisition Adding up to $60 Million in New Annual Revenue

by

CHARLOTTE, N.C., June 9, 2023 /PRNewswire/ — The company announced it had finally reached a definitive agreement with a significant infrastructure company to add up to $60 million in annual revenue, the first phase of a multi-phase series of transactions. “We started this process when Russ and Bob brought me in as Chief Executive over … Read more

Creative Medical Technology Holdings Announces Reverse Stock Split

by

PHOENIX, June 9, 2023 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the company’s Board of Directors has approved a reverse stock split of its shares of common stock at … Read more

NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering

by

RADNOR, Pa., June 9, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock. In … Read more